1	2	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Materials	_	_	NNS	_	_	_	_	_
2	and	_	_	CC	_	_	_	_	_
3	Methods	_	_	NNS	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	study	_	_	NN	_	_	_	_	_
3	was	_	_	VBD	_	_	_	_	_
4	designed	_	_	VBN	_	_	_	_	_
5	and	_	_	CC	_	_	_	_	_
6	developed	_	_	VBN	_	_	_	_	_
7	according	_	_	VBG	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	preferred	_	_	VBN	_	_	_	_	_
11	reporting	_	_	NN	_	_	_	_	_
12	items	_	_	NNS	_	_	_	_	_
13	for	_	_	IN	_	_	_	_	_
14	systematic	_	_	JJ	_	_	_	_	_
15	reviews	_	_	NNS	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	meta-analysis	_	_	NN	_	_	_	_	_
18	(	_	_	-LRB-	_	_	_	_	_
19	PRISMA	_	_	NN	_	_	_	_	_
20	)	_	_	-RRB-	_	_	_	_	_
21	guidelines	_	_	NNS	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	an	_	_	DT	_	_	_	_	_
24	evidence-based	_	_	JJ	_	_	_	_	_
25	set	_	_	NN	_	_	_	_	_
26	of	_	_	IN	_	_	_	_	_
27	minimum	_	_	JJ	_	_	_	_	_
28	items	_	_	NNS	_	_	_	_	_
29	for	_	_	IN	_	_	_	_	_
30	assessing	_	_	VBG	_	_	_	_	_
31	the	_	_	DT	_	_	_	_	_
32	benefits	_	_	NNS	_	_	_	_	_
33	and	_	_	CC	_	_	_	_	_
34	harms	_	_	NNS	_	_	_	_	_
35	of	_	_	IN	_	_	_	_	_
36	a	_	_	DT	_	_	_	_	_
37	given	_	_	VBN	_	_	_	_	_
38	healthcare	_	_	NN	_	_	_	_	_
39	intervention	_	_	NN	_	_	_	_	_
40	.	_	_	.	_	_	_	_	_


1	2.1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Literature	_	_	NN	_	_	_	_	_
2	Search	_	_	NN	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	searched	_	_	VBD	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	literature	_	_	NN	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	various	_	_	JJ	_	_	_	_	_
7	electronic	_	_	JJ	_	_	_	_	_
8	bibliographic	_	_	JJ	_	_	_	_	_
9	databases	_	_	NNS	_	_	_	_	_
10	(	_	_	-LRB-	_	_	_	_	_
11	PubMed/Medline	_	_	NNP	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	Embase	_	_	NNP	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	EBSCO	_	_	NNP	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	Cochrane	_	_	NNP	_	_	_	_	_
18	databases	_	_	NNS	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	Lilacs	_	_	NNP	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	Dialnet	_	_	NNP	_	_	_	_	_
24	)	_	_	-RRB-	_	_	_	_	_
25	for	_	_	IN	_	_	_	_	_
26	all	_	_	DT	_	_	_	_	_
27	entries	_	_	NNS	_	_	_	_	_
28	up	_	_	RP	_	_	_	_	_
29	until	_	_	IN	_	_	_	_	_
30	30	_	_	CD	_	_	_	_	_
31	March	_	_	NNP	_	_	_	_	_
32	2019	_	_	CD	_	_	_	_	_
33	,	_	_	,	_	_	_	_	_
34	without	_	_	IN	_	_	_	_	_
35	applying	_	_	VBG	_	_	_	_	_
36	any	_	_	DT	_	_	_	_	_
37	publication	_	_	NN	_	_	_	_	_
38	age	_	_	NN	_	_	_	_	_
39	limitations	_	_	NNS	_	_	_	_	_
40	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	reference	_	_	NN	_	_	_	_	_
3	lists	_	_	NNS	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	all	_	_	PDT	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	relevant	_	_	JJ	_	_	_	_	_
8	articles	_	_	NNS	_	_	_	_	_
9	were	_	_	VBD	_	_	_	_	_
10	manually	_	_	RB	_	_	_	_	_
11	cross-referenced	_	_	VBN	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	order	_	_	NN	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	identify	_	_	VB	_	_	_	_	_
16	any	_	_	DT	_	_	_	_	_
17	additional	_	_	JJ	_	_	_	_	_
18	articles	_	_	NNS	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	primary	_	_	JJ	_	_	_	_	_
3	search	_	_	NN	_	_	_	_	_
4	terms	_	_	NNS	_	_	_	_	_
5	used	_	_	VBN	_	_	_	_	_
6	for	_	_	IN	_	_	_	_	_
7	all	_	_	DT	_	_	_	_	_
8	six	_	_	CD	_	_	_	_	_
9	databases	_	_	NNS	_	_	_	_	_
10	were	_	_	VBD	_	_	_	_	_
11	‘	_	_	``	_	_	_	_	_
12	leucine	_	_	NN	_	_	_	_	_
13	’	_	_	''	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	‘	_	_	``	_	_	_	_	_
16	sarcopenia	_	_	NN	_	_	_	_	_
17	’	_	_	''	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	as	_	_	RB	_	_	_	_	_
20	well	_	_	RB	_	_	_	_	_
21	as	_	_	IN	_	_	_	_	_
22	one	_	_	CD	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	the	_	_	DT	_	_	_	_	_
25	following	_	_	VBG	_	_	_	_	_
26	terms	_	_	NNS	_	_	_	_	_
27	:	_	_	:	_	_	_	_	_
28	‘	_	_	``	_	_	_	_	_
29	older	_	_	JJR	_	_	_	_	_
30	’	_	_	''	_	_	_	_	_
31	,	_	_	,	_	_	_	_	_
32	‘	_	_	``	_	_	_	_	_
33	elderly	_	_	JJ	_	_	_	_	_
34	’	_	_	''	_	_	_	_	_
35	,	_	_	,	_	_	_	_	_
36	‘	_	_	``	_	_	_	_	_
37	disease	_	_	NN	_	_	_	_	_
38	’	_	_	''	_	_	_	_	_
39	or	_	_	CC	_	_	_	_	_
40	‘	_	_	``	_	_	_	_	_
41	trial	_	_	NN	_	_	_	_	_
42	’	_	_	''	_	_	_	_	_
43	.	_	_	.	_	_	_	_	_


1	2.2	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Inclusion	_	_	NN	_	_	_	_	_
2	and	_	_	CC	_	_	_	_	_
3	Exclusion	_	_	NN	_	_	_	_	_
4	Criteria	_	_	NNS	_	_	_	_	_


1	To	_	_	TO	_	_	_	_	_
2	answer	_	_	VB	_	_	_	_	_
3	our	_	_	PRP$	_	_	_	_	_
4	research	_	_	NN	_	_	_	_	_
5	questions	_	_	NNS	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	we	_	_	PRP	_	_	_	_	_
8	applied	_	_	VBD	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	following	_	_	VBG	_	_	_	_	_
11	inclusion	_	_	NN	_	_	_	_	_
12	criteria	_	_	NNS	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	each	_	_	DT	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	considered	_	_	VBN	_	_	_	_	_
18	manuscripts	_	_	NNS	_	_	_	_	_
19	:	_	_	:	_	_	_	_	_
20	(	_	_	-LRB-	_	_	_	_	_
21	1	_	_	CD	_	_	_	_	_
22	)	_	_	-RRB-	_	_	_	_	_
23	It	_	_	PRP	_	_	_	_	_
24	was	_	_	VBD	_	_	_	_	_
25	acknowledged	_	_	VBN	_	_	_	_	_
26	as	_	_	IN	_	_	_	_	_
27	an	_	_	DT	_	_	_	_	_
28	original	_	_	JJ	_	_	_	_	_
29	article	_	_	NN	_	_	_	_	_
30	;	_	_	:	_	_	_	_	_
31	we	_	_	PRP	_	_	_	_	_
32	included	_	_	VBD	_	_	_	_	_
33	experimental	_	_	JJ	_	_	_	_	_
34	studies	_	_	NNS	_	_	_	_	_
35	(	_	_	-LRB-	_	_	_	_	_
36	randomised	_	_	VBN	_	_	_	_	_
37	and	_	_	CC	_	_	_	_	_
38	placebo-controlled	_	_	JJ	_	_	_	_	_
39	trials	_	_	NNS	_	_	_	_	_
40	)	_	_	-RRB-	_	_	_	_	_
41	and	_	_	CC	_	_	_	_	_
42	observational	_	_	JJ	_	_	_	_	_
43	studies	_	_	NNS	_	_	_	_	_
44	(	_	_	-LRB-	_	_	_	_	_
45	cohort	_	_	NN	_	_	_	_	_
46	,	_	_	,	_	_	_	_	_
47	cross-sectional	_	_	JJ	_	_	_	_	_
48	,	_	_	,	_	_	_	_	_
49	and	_	_	CC	_	_	_	_	_
50	case-control	_	_	NN	_	_	_	_	_
51	studies	_	_	NNS	_	_	_	_	_
52	)	_	_	-RRB-	_	_	_	_	_
53	;	_	_	:	_	_	_	_	_
54	(	_	_	-LRB-	_	_	_	_	_
55	2	_	_	CD	_	_	_	_	_
56	)	_	_	-RRB-	_	_	_	_	_
57	it	_	_	PRP	_	_	_	_	_
58	was	_	_	VBD	_	_	_	_	_
59	a	_	_	DT	_	_	_	_	_
60	full	_	_	JJ	_	_	_	_	_
61	text	_	_	NN	_	_	_	_	_
62	published	_	_	VBN	_	_	_	_	_
63	either	_	_	CC	_	_	_	_	_
64	in	_	_	IN	_	_	_	_	_
65	English	_	_	NNP	_	_	_	_	_
66	,	_	_	,	_	_	_	_	_
67	Portuguese	_	_	NNP	_	_	_	_	_
68	,	_	_	,	_	_	_	_	_
69	or	_	_	CC	_	_	_	_	_
70	Spanish	_	_	NNP	_	_	_	_	_
71	;	_	_	:	_	_	_	_	_
72	(	_	_	-LRB-	_	_	_	_	_
73	3	_	_	CD	_	_	_	_	_
74	)	_	_	-RRB-	_	_	_	_	_
75	at	_	_	IN	_	_	_	_	_
76	least	_	_	JJS	_	_	_	_	_
77	one	_	_	CD	_	_	_	_	_
78	of	_	_	IN	_	_	_	_	_
79	the	_	_	DT	_	_	_	_	_
80	sarcopenia	_	_	NN	_	_	_	_	_
81	criteria	_	_	NNS	_	_	_	_	_
82	was	_	_	VBD	_	_	_	_	_
83	measured	_	_	VBN	_	_	_	_	_
84	:	_	_	:	_	_	_	_	_
85	Muscular	_	_	JJ	_	_	_	_	_
86	mass	_	_	NN	_	_	_	_	_
87	and/or	_	_	JJ	_	_	_	_	_
88	muscular	_	_	JJ	_	_	_	_	_
89	strength	_	_	NN	_	_	_	_	_
90	and/or	_	_	IN	_	_	_	_	_
91	physical	_	_	JJ	_	_	_	_	_
92	performance	_	_	NN	_	_	_	_	_
93	;	_	_	:	_	_	_	_	_
94	(	_	_	-LRB-	_	_	_	_	_
95	4	_	_	CD	_	_	_	_	_
96	)	_	_	-RRB-	_	_	_	_	_
97	a	_	_	DT	_	_	_	_	_
98	description	_	_	NN	_	_	_	_	_
99	of	_	_	IN	_	_	_	_	_
100	how	_	_	WRB	_	_	_	_	_
101	sarcopenia	_	_	NN	_	_	_	_	_
102	was	_	_	VBD	_	_	_	_	_
103	evaluated	_	_	VBN	_	_	_	_	_
104	was	_	_	VBD	_	_	_	_	_
105	defined	_	_	VBN	_	_	_	_	_
106	in	_	_	IN	_	_	_	_	_
107	the	_	_	DT	_	_	_	_	_
108	methods	_	_	NNS	_	_	_	_	_
109	section	_	_	NN	_	_	_	_	_
110	;	_	_	:	_	_	_	_	_
111	(	_	_	-LRB-	_	_	_	_	_
112	5	_	_	CD	_	_	_	_	_
113	)	_	_	-RRB-	_	_	_	_	_
114	the	_	_	DT	_	_	_	_	_
115	concentration	_	_	NN	_	_	_	_	_
116	of	_	_	IN	_	_	_	_	_
117	leucine	_	_	NN	_	_	_	_	_
118	used	_	_	VBN	_	_	_	_	_
119	in	_	_	IN	_	_	_	_	_
120	the	_	_	DT	_	_	_	_	_
121	intervention	_	_	NN	_	_	_	_	_
122	was	_	_	VBD	_	_	_	_	_
123	specified	_	_	VBN	_	_	_	_	_
124	or	_	_	CC	_	_	_	_	_
125	could	_	_	MD	_	_	_	_	_
126	be	_	_	VB	_	_	_	_	_
127	calculated	_	_	VBN	_	_	_	_	_
128	.	_	_	.	_	_	_	_	_


1	Studies	_	_	NNS	_	_	_	_	_
2	performed	_	_	VBN	_	_	_	_	_
3	in	_	_	IN	_	_	_	_	_
4	animals	_	_	NNS	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	case-report	_	_	NN	_	_	_	_	_
7	studies	_	_	NNS	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	letters	_	_	NNS	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	Editor	_	_	NNP	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	abstracts	_	_	NNS	_	_	_	_	_
15	from	_	_	IN	_	_	_	_	_
16	conferences	_	_	NNS	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	books	_	_	NNS	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	PhD	_	_	NN	_	_	_	_	_
21	theses	_	_	NNS	_	_	_	_	_
22	were	_	_	VBD	_	_	_	_	_
23	excluded	_	_	VBN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	2.3	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Data	_	_	NN	_	_	_	_	_
2	Collection	_	_	NN	_	_	_	_	_
3	and	_	_	CC	_	_	_	_	_
4	Analysis	_	_	NN	_	_	_	_	_


1	Details	_	_	NNS	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	manuscripts	_	_	NNS	_	_	_	_	_
5	identified	_	_	VBN	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	literature	_	_	NN	_	_	_	_	_
9	search	_	_	NN	_	_	_	_	_
10	were	_	_	VBD	_	_	_	_	_
11	uploaded	_	_	VBN	_	_	_	_	_
12	into	_	_	IN	_	_	_	_	_
13	a	_	_	DT	_	_	_	_	_
14	web-based	_	_	JJ	_	_	_	_	_
15	system	_	_	NN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	which	_	_	WDT	_	_	_	_	_
18	was	_	_	VBD	_	_	_	_	_
19	used	_	_	VBN	_	_	_	_	_
20	to	_	_	TO	_	_	_	_	_
21	manage	_	_	VB	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	screening	_	_	NN	_	_	_	_	_
24	process	_	_	NN	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	remove	_	_	VB	_	_	_	_	_
27	any	_	_	DT	_	_	_	_	_
28	duplicate	_	_	JJ	_	_	_	_	_
29	citations	_	_	NNS	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	order	_	_	NN	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	determine	_	_	VB	_	_	_	_	_
5	which	_	_	WDT	_	_	_	_	_
6	studies	_	_	NNS	_	_	_	_	_
7	would	_	_	MD	_	_	_	_	_
8	be	_	_	VB	_	_	_	_	_
9	included	_	_	VBN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	three	_	_	CD	_	_	_	_	_
12	members	_	_	NNS	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	review	_	_	NN	_	_	_	_	_
16	team	_	_	NN	_	_	_	_	_
17	independently	_	_	RB	_	_	_	_	_
18	screened	_	_	VBD	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	titles	_	_	NNS	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	abstracts	_	_	NNS	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	these	_	_	DT	_	_	_	_	_
25	articles	_	_	NNS	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	the	_	_	DT	_	_	_	_	_
28	full	_	_	JJ	_	_	_	_	_
29	texts	_	_	NNS	_	_	_	_	_
30	were	_	_	VBD	_	_	_	_	_
31	retrieved	_	_	VBN	_	_	_	_	_
32	based	_	_	VBN	_	_	_	_	_
33	on	_	_	IN	_	_	_	_	_
34	our	_	_	PRP$	_	_	_	_	_
35	inclusion	_	_	NN	_	_	_	_	_
36	and	_	_	CC	_	_	_	_	_
37	exclusion	_	_	NN	_	_	_	_	_
38	criteria	_	_	NNS	_	_	_	_	_
39	.	_	_	.	_	_	_	_	_


1	Two	_	_	CD	_	_	_	_	_
2	reviewers	_	_	NNS	_	_	_	_	_
3	independently	_	_	RB	_	_	_	_	_
4	extracted	_	_	VBD	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	following	_	_	VBG	_	_	_	_	_
7	data	_	_	NNS	_	_	_	_	_
8	from	_	_	IN	_	_	_	_	_
9	each	_	_	DT	_	_	_	_	_
10	article	_	_	NN	_	_	_	_	_
11	:	_	_	:	_	_	_	_	_
12	The	_	_	DT	_	_	_	_	_
13	country	_	_	NN	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	which	_	_	WDT	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	study	_	_	NN	_	_	_	_	_
18	was	_	_	VBD	_	_	_	_	_
19	conducted	_	_	VBN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	number	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	participants	_	_	NNS	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	age	_	_	NN	_	_	_	_	_
26	of	_	_	IN	_	_	_	_	_
27	the	_	_	DT	_	_	_	_	_
28	participants	_	_	NNS	_	_	_	_	_
29	at	_	_	IN	_	_	_	_	_
30	the	_	_	DT	_	_	_	_	_
31	time	_	_	NN	_	_	_	_	_
32	of	_	_	IN	_	_	_	_	_
33	inclusion	_	_	NN	_	_	_	_	_
34	,	_	_	,	_	_	_	_	_
35	sex	_	_	NN	_	_	_	_	_
36	of	_	_	IN	_	_	_	_	_
37	the	_	_	DT	_	_	_	_	_
38	participants	_	_	NNS	_	_	_	_	_
39	,	_	_	,	_	_	_	_	_
40	amount	_	_	NN	_	_	_	_	_
41	of	_	_	IN	_	_	_	_	_
42	leucine	_	_	NN	_	_	_	_	_
43	administered	_	_	VBN	_	_	_	_	_
44	,	_	_	,	_	_	_	_	_
45	co-administration	_	_	NN	_	_	_	_	_
46	of	_	_	IN	_	_	_	_	_
47	other	_	_	JJ	_	_	_	_	_
48	substances	_	_	NNS	_	_	_	_	_
49	,	_	_	,	_	_	_	_	_
50	sarcopenia	_	_	NN	_	_	_	_	_
51	evaluation	_	_	NN	_	_	_	_	_
52	methods	_	_	NNS	_	_	_	_	_
53	,	_	_	,	_	_	_	_	_
54	and	_	_	CC	_	_	_	_	_
55	the	_	_	DT	_	_	_	_	_
56	main	_	_	JJ	_	_	_	_	_
57	and	_	_	CC	_	_	_	_	_
58	secondary	_	_	JJ	_	_	_	_	_
59	outcomes	_	_	NNS	_	_	_	_	_
60	of	_	_	IN	_	_	_	_	_
61	the	_	_	DT	_	_	_	_	_
62	study	_	_	NN	_	_	_	_	_
63	.	_	_	.	_	_	_	_	_


1	Any	_	_	DT	_	_	_	_	_
2	disagreement	_	_	NN	_	_	_	_	_
3	between	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	reviewers	_	_	NNS	_	_	_	_	_
6	regarding	_	_	VBG	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	papers	_	_	NNS	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	data	_	_	NNS	_	_	_	_	_
11	extracted	_	_	VBN	_	_	_	_	_
12	from	_	_	IN	_	_	_	_	_
13	them	_	_	PRP	_	_	_	_	_
14	was	_	_	VBD	_	_	_	_	_
15	resolved	_	_	VBN	_	_	_	_	_
16	by	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	third	_	_	JJ	_	_	_	_	_
19	author	_	_	NN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	2.4	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Assessment	_	_	NN	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	Bias	_	_	NNP	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	assessed	_	_	VBD	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	risk	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	bias	_	_	NN	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	each	_	_	DT	_	_	_	_	_
9	randomised	_	_	JJ	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	placebo-controlled	_	_	JJ	_	_	_	_	_
12	study	_	_	NN	_	_	_	_	_
13	according	_	_	VBG	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	Cochrane	_	_	NNP	_	_	_	_	_
17	Review	_	_	NNP	_	_	_	_	_
18	guidelines	_	_	NNS	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	which	_	_	WDT	_	_	_	_	_
21	cover	_	_	VBP	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	following	_	_	VBG	_	_	_	_	_
24	bias	_	_	NN	_	_	_	_	_
25	domains	_	_	NNS	_	_	_	_	_
26	:	_	_	:	_	_	_	_	_
27	Selection	_	_	NN	_	_	_	_	_
28	bias	_	_	NN	_	_	_	_	_
29	(	_	_	-LRB-	_	_	_	_	_
30	random	_	_	JJ	_	_	_	_	_
31	sequence	_	_	NN	_	_	_	_	_
32	generation	_	_	NN	_	_	_	_	_
33	and	_	_	CC	_	_	_	_	_
34	allocation	_	_	NN	_	_	_	_	_
35	concealment	_	_	NN	_	_	_	_	_
36	)	_	_	-RRB-	_	_	_	_	_
37	,	_	_	,	_	_	_	_	_
38	performance	_	_	NN	_	_	_	_	_
39	bias	_	_	NN	_	_	_	_	_
40	(	_	_	-LRB-	_	_	_	_	_
41	blinding	_	_	NN	_	_	_	_	_
42	of	_	_	IN	_	_	_	_	_
43	participants	_	_	NNS	_	_	_	_	_
44	and	_	_	CC	_	_	_	_	_
45	personnel	_	_	NNS	_	_	_	_	_
46	)	_	_	-RRB-	_	_	_	_	_
47	,	_	_	,	_	_	_	_	_
48	detection	_	_	NN	_	_	_	_	_
49	bias	_	_	NN	_	_	_	_	_
50	(	_	_	-LRB-	_	_	_	_	_
51	blinding	_	_	VBG	_	_	_	_	_
52	the	_	_	DT	_	_	_	_	_
53	outcome	_	_	NN	_	_	_	_	_
54	assessment	_	_	NN	_	_	_	_	_
55	)	_	_	-RRB-	_	_	_	_	_
56	,	_	_	,	_	_	_	_	_
57	attrition	_	_	NN	_	_	_	_	_
58	bias	_	_	NN	_	_	_	_	_
59	(	_	_	-LRB-	_	_	_	_	_
60	incomplete	_	_	JJ	_	_	_	_	_
61	outcome	_	_	NN	_	_	_	_	_
62	data	_	_	NNS	_	_	_	_	_
63	)	_	_	-RRB-	_	_	_	_	_
64	,	_	_	,	_	_	_	_	_
65	and	_	_	CC	_	_	_	_	_
66	reporting	_	_	NN	_	_	_	_	_
67	bias	_	_	NN	_	_	_	_	_
68	(	_	_	-LRB-	_	_	_	_	_
69	selective	_	_	JJ	_	_	_	_	_
70	reporting	_	_	NN	_	_	_	_	_
71	)	_	_	-RRB-	_	_	_	_	_
72	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	judgments	_	_	NNS	_	_	_	_	_
3	were	_	_	VBD	_	_	_	_	_
4	made	_	_	VBN	_	_	_	_	_
5	independently	_	_	RB	_	_	_	_	_
6	by	_	_	IN	_	_	_	_	_
7	two	_	_	CD	_	_	_	_	_
8	researchers	_	_	NNS	_	_	_	_	_
9	(	_	_	-LRB-	_	_	_	_	_
10	FM	_	_	NNP	_	_	_	_	_
11	-	_	_	:	_	_	_	_	_
12	M	_	_	NNP	_	_	_	_	_
13	–	_	_	:	_	_	_	_	_
14	A	_	_	NNP	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	R-F-V	_	_	NNP	_	_	_	_	_
17	)	_	_	-RRB-	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	with	_	_	IN	_	_	_	_	_
20	any	_	_	DT	_	_	_	_	_
21	discrepancies	_	_	NNS	_	_	_	_	_
22	resolved	_	_	VBN	_	_	_	_	_
23	with	_	_	IN	_	_	_	_	_
24	the	_	_	DT	_	_	_	_	_
25	third	_	_	JJ	_	_	_	_	_
26	author	_	_	NN	_	_	_	_	_
27	(	_	_	-LRB-	_	_	_	_	_
28	OC	_	_	NNP	_	_	_	_	_
29	)	_	_	-RRB-	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_

